Managing Adverse Effects from Bispecific Antibodies in Multiple Myeloma

Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Recent advancements in multiple myeloma treatment highlight the efficacy of daratumumab combined with VRd, showcasing improved outcomes and tolerability.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

No TRAEs leading to dose discontinuation, DLTs, or belantamab-related corneal events above grade 1 occurred with belantamab in multiple myeloma.

Updated findings from AURIGA support the value of adding subcutaneous daratumumab to lenalidomide maintenance in MRD-positive NDMM after transplant.